BIOINVENT INTERNATIONAL AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.2 SEK | -1.93% |
|
+15.93% | +101.48% |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to the BioInvent KOL...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Companyâs operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
Calendar
29/08/2024
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
38.95
SEK
Average target price
83
SEK
Spread / Average Target
+113.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +101.48% | 243M | |
| +16.81% | 122B | |
| +20.01% | 115B | |
| +21.22% | 26.64B | |
| -23.42% | 19.91B | |
| -17.47% | 16.32B | |
| -45.95% | 15.52B | |
| -18.72% | 15.49B | |
| +61.59% | 14.83B | |
| +3.32% | 13.67B |
- Stock Market
- Equities
- BINV Stock
- News BioInvent International AB
- Transcript : BioInvent International AB - Special Call
